<DOC>
	<DOCNO>NCT01507194</DOCNO>
	<brief_summary>This study evaluate single IV dos Vestipitant ( GW597599 ) compare 4 mg IV ondansetron treat breakthrough postoperative nausea vomiting ( PONV ) failure PONV prophylaxis regimen include 4 mg IV ondansetron .</brief_summary>
	<brief_title>A Study Vestipitant ( GW597599 ) Treatment Breakthrough Postoperative Nausea Vomiting ( PONV )</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Postoperative Nausea Vomiting</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Vestipitant</mesh_term>
	<mesh_term>Neurokinin-1 Receptor Antagonists</mesh_term>
	<criteria>Male Female postoperative surgical subject age 1875 year . Female subject nonchildbearing potential childbearing potential agrees use specify contraception method . Has 3 follow independent risk factor PONV : female gender ; nonsmoker ; history PONV motion sickness ; plan post operative opioids . Has receive one dose ondansetron part PONV prophylaxis regimen surgical procedure . Has receive general anesthesia . Meets ASA Physical Status Classification 1 2 without `` E '' modifier preoperatively day surgery hematology blood chemistry value within acceptable limit surgery . Is capable give write informed consent . Experiences breakthrough PONV define : postoperative nausea â‰¥ 7 Nausea Numeric Rating Scale ; nausea result subject request antiemetic ; episode emesis retching . A history HIV . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month Screening . An ALT AST &gt; 2.5 x ULN Screening . Pregnant lactate female . The subject schedule undergo laparoscopic biopsy . The subject history schedule undergo cardiac/cardiothoracic surgery . The subject schedule receive neuraxial anesthesia ( e.g. , epidural , spinal , caudal anesthesia ) total IV anesthesia . The subject schedule receive propofol maintenance anesthesia ( propofol induction agent allow ) . The subject schedule receive NK1 inhibitor ( aprepitant/fosaprepitant ) part PONV prophylaxis regimen surgical procedure . The subject schedule gastric content suction continuously surgical procedure via nasogastric tube , nasogastric oral gastric tube postoperative period . A single pas begin end procedure , intraoperative gastric suction air , permit . The subject receive investigational drug within 30 day schedule receive investigational drug addition vestipitant study period . The subject persistent recurrent nausea and/or vomit due etiology , include , limited , gastric outlet obstruction , hypercalcemia , active peptic ulcer , increase intracranial pressure , chemotherapy , brain metastasis . The subject receive radiation therapy abdomen pelvis within 7 day prior receive study medication and/or receive radiation therapy abdomen pelvis evaluation period . The subject history wound dehiscence . The subject history illness might pose unacceptable risk administer study medication . The subject current past medical condition ( e.g. , vagotomy ) and/or require medication treat condition could affect evaluation study . The subject know contraindication hypersensitivity ondansetron ondansetron injection , schedule anaesthetic analgesic agent , vestipitant component vestipitant formulation include Captisol . The subject receive medication know potential antiemetic activity induction anaesthesia ( intraoperative post operative period ) plan Study Treatment . Current plan use strong moderate inhibitor CYP3A within 7 day inducer CYP3A within 14 day prior study medication administration . The subject unwilling unable follow procedure outline protocol . The subject mentally legally incapacitate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>